Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 Over Twelve Years in a Consecutive Clinical Cohort

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Causes of Death in People with Dementia from 2002 to 2015: A Nationwide Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Dementia and COVID-19, a Bidirectional Liaison: Risk Factors, Biomarkers, and Optimal Health Care

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Is the Frontal Lobe the Primary Target of SARS-CoV-2?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Hospital readmissions following infections in dementia: a nationwide and registry-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Associations between oxidative stress and perceived stress in patients with bipolar disorder and healthy control individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Barriers in access to dementia care in minority ethnic groups in Denmark: a qualitative study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Dementia increases mortality beyond effects of comorbid conditions: A national registry-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Amyloid-β 1-42 (Aβ1-42) measured in the cerebrospinal fluid (CSF) can be used as a diagnostic biomarker for Alzheimer's disease (AD) but an upward drift when using the INNOTEST ELISA has been suggested. We investigated the upwards drift of Aβ1-42 levels over a period of twelve years in a consecutive memory clinic cohort. We found a significant increase in Aβ1-42 from 2008 to 2019 independent of changes in tau. New methods for the quantification of CSF Aβ1-42 levels are being implemented but awareness of this upwards drift is crucial during the diagnostic work-up and when selecting historical samples for research.

OriginalsprogEngelsk
TidsskriftJournal of Alzheimer's Disease
Vol/bind81
Udgave nummer4
Sider (fra-til)1369-1373
Antal sider5
ISSN1387-2877
DOI
StatusUdgivet - 2021

ID: 68350946